What do systematic reviews say?

Supervised exercise therapy vs home exercises

• Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 68 participants
  Low

Supervised exercise therapy vs home exercises

• Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 62 participants
  Very low

Supervised exercise therapy vs walking advice

• Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication 2018 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 624 participants
  High

Supervised exercise therapy vs walking advice

• Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication 2018 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 508 participants
  High

Supervised exercise therapy vs walking advice

• Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 296 participants
  Low

Supervised exercise therapy vs walking advice

• Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication 2018 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 296 participants
  Low

Rutosides vs placebo (or no treatment)

The review found no eligible studies for this question.

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rutosides vs an alternative venoactive remedy (hidrosmina)

Rutosides may leads to lower improvement in PTS (6 months) compared with an alternative venoactive remedy (hidrosmina) (low certainty).

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  OR 0.18 [0.04, 0.94]
  1 study · 29 participants
  Low

Rutosides vs an alternative venoactive remedy (hidrosmina)

Rutosides showed no clear difference in deterioration in PTS (6 months) compared with an alternative venoactive remedy (hidrosmina) (low certainty).

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  OR 0.19 [0.01, 4.24]
  1 study · 29 participants
  Low

Rutosides vs an alternative venoactive remedy (hidrosmina)

The review found no eligible studies for this question.

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rutosides vs placebo (or no treatment)

Rutosides showed no clear difference in improvement in PTS (8 weeks ‐ 12 months) compared with placebo (or no treatment) (low certainty).

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  OR 1.29 [0.69, 2.41]
  2 studies · 164 participants
  Low

Rutosides vs placebo (or no treatment)

Rutosides showed no clear difference in deterioration in PTS (8 weeks ‐ 12 months) compared with placebo (or no treatment) (low certainty).

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  OR 0.61 [0.19, 1.9]
  1 study · 80 participants
  Low

Rutosides vs placebo (or no treatment)

The review found no eligible studies for this question.

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rutosides vs compression stockings

The review found no eligible studies for this question.

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rutosides vs compression stockings

Rutosides showed no clear difference in improvement in PTS (12 months) compared with elastic compression stockings (low certainty).

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  OR 0.8 [0.31, 2.03]
  1 study · 80 participants
  Low

Rutosides vs compression stockings

Rutosides showed no clear difference in deterioration in PTS (12 months) compared with elastic compression stockings (low certainty).

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  OR 0.61 [0.19, 1.9]
  1 study · 80 participants
  Low

Rutosides vs compression stockings

The review found no eligible studies for this question.

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Rutosides vs an alternative venoactive remedy (hidrosmina)

The review found no eligible studies for this question.

• Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Prostanoids vs placebo

Prostanoids showed no clear difference in cardiovascular mortality compared with placebo (low certainty).

• Prostanoids for critical limb ischaemia 2018 · Cochrane Headline outcomes only
  RR 0.81 [0.41, 1.58]
  3 studies · 1170 participants
  Low

Prostanoids vs pentoxifylline

It is very uncertain whether prostanoids changes adverse events (participants) compared with pentoxifylline (very low certainty).

• Prostanoids for critical limb ischaemia 2018 · Cochrane Headline outcomes only
  RR 0.6 [0.24, 1.47]
  1 study · 70 participants
  Very low